Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective

Jacqueline Costello¹,², Matthew Kang³,⁴ and Versha Banerji⁵,⁶,*

Abstract: From a Canadian perspective, there has been a limited discussion on the frontline management of young, fit patients with chronic lymphocytic leukemia (CLL). The prevalence of this population ranges between 2 and 22 per 100,000 persons in Canada and varies by region. Until recently, fixed-duration fludarabine-based chemoimmunotherapy (CIT) was the primary treatment option in Canada for this patient population. The ECOG1912 trial has since demonstrated that ibrutinib and rituximab therapy are as effective as fludarabine-cyclophosphamide-rituximab (FCR) in this population. The ALLIANCE trial showed that rituximab added no incremental benefit to ibrutinib. Canadian payors and physicians adopted ibrutinib monotherapy as the CLL standard of care, even in the young, fit population, although frontline ibrutinib therapy is often reimbursed by provincial public drug plans only in patients with high-risk disease or those who are unfit to receive fludarabine. Young, fit patients with CLL and their physicians may now choose between continuous ibrutinib monotherapy and fixed-duration CIT with FCR. Factors affecting this choice include patient preference and the short- and long-term toxicity profiles of both regimens, and a risk-based algorithm is provided. As new continuous-therapy options enter the market, all treatment choices present benefits and risks that must be communicated to the patient.

Keywords: chronic lymphocytic leukemia; CLL; frontline treatment; algorithm; Canadian

1. Introduction

Chronic lymphocytic leukemia (CLL) is characterized by the proliferation and accumulation of small, mature B lymphocytes within the blood, bone marrow, lymph nodes, and other lymphoid tissues [1]. Canadian cancer incidence statistics from 2018 observed that 1725 Canadians (rate of 6.0/100,000 population) were newly diagnosed with CLL [2]. By extrapolation, there may have been over 2000 cases in Canada based on the 2019 population. The most recent mortality statistics for Canada are from 2017, when 611 Canadians (59% male) died from CLL [3].

These data indicate the importance of optimally managing patients with CLL. While there are published review articles on the frontline management of CLL, few have discussed the young, fit patient from a Canadian perspective [4,5]. Therefore, the goal of this manuscript is to provide treating clinicians with evidence-based and practical guidance on managing their young, fit patients with CLL.

For many years, the standard frontline treatment option for the young, fit patient with CLL was fixed-duration chemotherapy or chemoimmunotherapy (CIT) [6]. Recently, the ECOG1912 clinical trial observed that continuous therapy with the Bruton’s tyrosine
kinase (BTK) inhibitor ibrutinib improved overall survival (OS) when compared to FCR [7]. The clinical importance of ECOG1912, and future continuous therapy trials, is providing young, fit patients with CLL a nonchemotherapy treatment option, especially in high-risk individuals. This change in clinical practice is made even more important in this patient population as it opens a dialogue and enables the patient to be more involved in their treatment choice.

2. Defining the Young, Fit Patient with CLL

For the purpose of this review, the young, fit patient with CLL is defined as a patient 65 years of age and younger; has a Cumulative Illness Rating Scale (CIRS) score of less than 6; has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2; and is often free of cardiac and renal disease (creatinine clearance $\geq$ 60 mL/min). Clinical trials have frequently used age 65 years or younger as a cutoff and have often limited participants to those with an ECOG performance status of 2 or lower [8,9]. It is acknowledged that some clinicians may employ a more general approach to assessing fitness, combining a patient’s overall appearance and ease of movement. Risk assessments for patients with CLL can start by using the Rai or Binet staging systems—the Rai system is more commonly used in Canada [10]. Additional prognostic parameters include biomarkers (ie, IGHV mutational status, serum $\beta_2$-microglobulin and the presence of del(17p) and/or TP53 mutations [11]. Among these, IGHV status, del(17p), or TP53 mutations are considered predictive, and most Canadian clinicians use these biomarkers to guide individualized therapy. At present, IGHV mutational status, del(17p), and TP53 testing appear sufficient to guide treatment in the young, fit population. Testing for all is generally available across Canada, albeit with limited regional access and funding for TP53 testing. The CLL-international prognostic index (CLL-IPI) score is a prognostic score derived to identify high-risk disease by leveraging IGHV mutational status, age, stage, serum $\beta_2$-microglobulin, and the presence of del(17p) and TP53 mutations. This cumulative score incorporates clinical, biochemical, and molecular profiling and allows prediction of 5-year and 10-year OS based on risk stratification [12]. These outcomes were largely based in an era when chemotherapy was used. Although the CLL-IPI score is not widely used in Canada, and while it cannot be applied against all treatments, it is gaining momentum as these tests become more available and may be required for entry into some clinical trials to better stratify patients. Further investigation is needed to evaluate the 5- and 10-year risk stratified predictions with novel therapies.

Although the young, fit patient is defined above, grey zones within a clinical practice are common. Patients between the ages of 65 and 70 years may warrant being treated as young and fit, or not, depending on individual characteristics and comorbidities. In addition, a patient’s functional age may vary: for example, a 65-year-old with multiple comorbidities may have a similar health status to a healthy 80-year-old. The proportion of the 2018 Canadian population with CLL that would be considered young and fit also varies by region [13], with incidence rates ranging from between 2 and 4 per 100,000 population in Manitoba, Nova Scotia, Saskatchewan, and British Columbia, to greater than 4 to 7 per 100,000 population in Alberta, Ontario, and New Brunswick (Figure 1). These data indicate potential disparities in registries capturing the incidence of cancers, such as CLL, across the provinces and territories of Canada. Ongoing advocacy is required to ensure that cancer incidence is captured by these databases accurately.

The young, fit CLL population is associated with several advantages for treatment, including fewer comorbidities and the ability to tolerate CIT and treatment-related toxicities. However, few clinical trials have focused on this population to truly explore the optimal treatment choices in the context of their circumstances and needs, which may include employment, lifestyle, the impact of delayed adverse events, and overall patient preference.
3. First-Line Treatment Evolution in the Young, Fit Population

Until recently, fixed-duration fludarabine-based CIT was the primary treatment option in Canada for young, fit patients with CLL. However, over the past decade, foundational research has identified key pathways that can be targeted in patients with CLL. For example, B-cell receptor (BCR) signalling is essential for the proliferation and survival of CLL cells [6]. Kinases immediately downstream of the BCR, such as spleen tyrosine kinase (SYK) and phosphatidylinositol 3-kinase (PI3K), along with downstream amplification kinases like BTK are activated in many patients with CLL and appear essential to several CLL survival pathways [6]. In addition, CD20, a protein expressed on the surfaces of most B-cell malignancies including CLL, participates in BCR activation and signalling [14]. Chronic lymphocytic leukemia is also characterized by high levels of B-cell lymphoma 2 (BCL-2) protein, which is involved in inactivating apoptosis [14] and allowing CLL cells to evade cell death. Furthermore, loss of function of tumour suppressor genes such as TP53, ataxia telangiectasia mutated (ATM), and other somatic gene mutations (ie, SF3B-1) or complex karyotypes lead to chemotherapy-resistance in CLL [15,16]. A number of clinically approved agents have been developed to target these pathways and proteins, including acalabrutinib (BTK inhibitor), ibrutinib (BTK inhibitor), idelalisib (PI3Kδ inhibitor), obinutuzumab (anti-CD20 antibody), rituximab (anti-CD20 antibody), and venetoclax (BCL-2 inhibitor).

Currently, evidence for frontline treatment in the young, fit CLL population is lacking for the majority of these agents. Most studies have involved the older, less fit population, or have been performed in the relapsed/refractory setting [17–22]. The pivotal trials that have directly impacted the frontline treatment of young, fit patients with CLL are shown in Table 1. Figure 2 illustrates the timeline of events that have influenced treatment availability for this population.
Table 1. Pivotal first-line trials in young, fit patients with CLL that affected the Canadian landscape.

| Trial       | Agents             | ORR            | Median PFS          | Median OS                     | Del(17p) Inclusion | Median Age, Years | n   | Median Follow-Up, Years |
|-------------|--------------------|----------------|---------------------|------------------------------|--------------------|-------------------|-----|------------------------|
| CLL4 [23]   | FC vs. F vs. Clb   | 94% vs. 80% vs.| 36% vs. 10% at 5 yrs| 34.2% vs. 36.6% vs. 30.0%    | 7% vs. 8% vs. 6%   | 65 vs. 64 vs. 65  | 777 | 3.4                    |
| CLL5 [24]   | FC vs. F           | 94% vs. 83%    | 48 vs. 20 months    | 80.3% vs. 80.7% at 3 yrs      | NA                 | 58 vs. 59         | 375 | 1.8                    |
| E2997 [25]  | FC vs. F           | 74.3% vs. 59.5%| 31.6 vs. 19.2 months| 79% vs. 80% est at 2 yrs      | 10% vs. 9%         | 61 vs. 61         | 278 | 2.17                   |
| C9011 [26]  | F vs. Clb          | 63% vs. 37% at | 20 vs. 13 months    | 63 vs. 59 months              | NA                 | 64 vs. 62         | 544 | -15                    |
| Knauf et al. [27] | B vs. Clb    | 34.6% vs. 29.9%| 21.2 vs. 8.8 months| NR vs. 78.8 months            | NA                 | 63 vs. 64         | 319 | 4.5                    |
| CLL8 [9]    | FCR vs. FC         | 90% vs. 80%    | 56.8 vs. 32.9 months| NR vs. 86 months              | 7% vs. 10%         | 61 vs. 817        | 5.9 |                       |
| CLL10 ≤ 65 years [8] | BR vs. FCR  | 98% vs. 95%    | 38.5 vs. 53.6 months| NA                           | 0%                 | ≤ 65             | 367 | 3.1                    |
| ECOG-ACRIN 1912 [7] | Ibr + R vs. FCR | 95.8% vs. 81.1%| 89.4% vs. 72.9% at 3 yrs| 98.8% vs. 91.5% at 3 yrs | 0%                 | 56.7             | 529 | 2.8                    |

B = bendamustine; BR = bendamustine and rituximab; Clb = chlorambucil; F = fludarabine; FC = fludarabine and cyclophosphamide; FCR = fludarabine, cyclophosphamide and rituximab; Ibr = ibrutinib; ORR = overall response rate; R = rituximab.

Considerable changes have occurred over the past two decades. Before the availability of novel targeted therapies, chlorambucil was the standard of care for 40 years [28]. In 2000, the CALGB 9011 trial demonstrated the superior progression-free survival (PFS) of fludarabine over chlorambucil, and fludarabine became the new standard of care, despite not improving OS [28]. Six years later, the combination of fludarabine and cyclophosphamide (FC) showed incremental PFS benefit over fludarabine monotherapy in CLL5 [24], reinforced shortly thereafter by both E2997 [25] and CLL4 [23], although, again, no differences were seen in OS.

The addition of rituximab to FC turned chemotherapy into chemoimmunotherapy, and CLL8 was the first trial to show a survival benefit for fludarabine, cyclophosphamide, and rituximab (FCR) over FC [29]. CLL10 compared FCR to another commonly used CIT, bendamustine and rituximab (BR). FCR was found to have significantly longer PFS in the
intention-to-treat (ITT) population, and especially in the younger population [8], firmly entrenching FCR as the standard of care for young, fit patients with CLL. Long-term results have further confirmed its efficacy (Figure 3).

The ECOG1912 study published in 2019 comparing FCR to ibrutinib and rituximab (IR) was practice-changing [7]. For the first time, young, fit patients could be treated without chemotherapy, while benefitting from improved PFS and OS. ECOG1912 randomized treatment-naïve patients with CLL aged 70 years or younger in a 2:1 ratio to receive six cycles of IR (after a single cycle of ibrutinib alone) followed by ibrutinib alone until disease progression, or six cycles of FCR. At three years, there had been four deaths in the ibrutinib arm (one due to CLL) and 10 in the FCR arm (four due to CLL and two to therapy-related acute myeloid leukemia) (Figure 4). The statistically significant improvement in OS is a main reason Canadian clinicians readily adopted ibrutinib in their young, fit patients with CLL. There was also a significant difference in PFS seen in the IGHV-unmutated population (Figure 5), further highlighting the population where ibrutinib provides the most benefit versus FCR. There was no difference in PFS in IGHV-mutated patients, allowing clinicians and patients to engage in a dialogue on preferred treatment characteristics and to discuss the treatment goals in this population, including balancing the short- and long-term risks of time-limited chemotherapy versus continuous ibrutinib-based therapy.

During the ECOG1912 trial, therapy with ibrutinib occasionally needed to be adjusted or paused for adverse effect management, in a manner as described in the Product Monograph. Additional ECOG1912 results presented at American Society of Hematology (ASH) Annual Meeting & Exposition 2019 [31] showed that patients in whom therapy was held or discontinued for reasons other than progressive disease (after receiving a median of 15.1 months of ibrutinib therapy) obtained an additional 23 months (median) of PFS benefit without further treatment. While evidence is still being generated, this raises the question of time-limited therapy with BTK inhibitor, and whether it may be feasible to restart treatment after a prolonged treatment-free interval. The RESONATE-2 and PCYC-1102 clinical trials provide important long-term evidence for the safety and efficacy of ibrutinib in patients with CLL, including in those with high-risk features [32,33]. However, the studied populations were older and, as such, are out of scope for this review, which is focused on the young, fit patient.
During the ECOG1912 trial, therapy with ibrutinib occasionally needed to be adjusted or paused for adverse effect management, in a manner as described in the Product Monograph. Additional ECOG1912 results presented at American Society of Hematology (ASH) Annual Meeting & Exposition 2019 showed that patients in whom therapy was held or discontinued for reasons other than progressive disease (after receiving a median of 15.1 months of ibrutinib therapy) obtained an additional 23 months (median) of PFS.

Figure 4. Overall survival in E1912 (intention-to-treat population). Adapted from [31]. CI = confidence interval.

Figure 5. Progression-free survival of patients with CLL in E1912. Adapted from [31].

The question of whether rituximab adds incremental benefit to ibrutinib alone was addressed in the ALLIANCE trial (A041202), albeit in an older but equally fit population [20]. This trial showed no difference in outcomes between ibrutinib alone versus IR. As a result, Canadian payors and physicians have adopted ibrutinib monotherapy as the CLL standard of care, even in the young, fit population. In the United States, after the E1912 results
came out, the National Comprehensive Cancer Network (NCCN) guidelines altered their treatment recommendations in favour of frontline ibrutinib in young, fit patients.

4. Provincial Differences in Coverage

In Canada, public and private formularies, which regulate drug reimbursements, play a significant role in how novel therapeutics are used. Listing criteria in the various provincial formularies (which list drugs that are paid for by the government for eligible groups) vary widely, and their initial inclusion of a BTK inhibitor occurred over a period of four years, with the first funding of ibrutinib occurring in British Columbia in 2016, and most recently reimbursed in Prince Edward Island in 2020 [34]. For previously untreated patients with CLL, the reimbursement criteria implemented by provincial public drug plans across the country have generally limited the use of BTK inhibitors to patients who have high-risk disease features (independent of age) and/or those who are unfit to receive fludarabine (which might include age).

At the same time as these funding criteria were being developed, Canadian physicians were gaining access to cytogenetic and molecular profiling, including IGHV mutation status, TP53 mutation status, and the fluorescence in situ hybridization (FISH) panel that detected the presence of the del(11q), del(13q), del(17p), and trisomy 12 mutations. Access to these important biomarkers also varies by province. More recently, the Canadian Agency for Drugs and Technologies in Health (CADTH) has updated its treatment algorithm to include consideration of novel therapies in younger, not fit for FCR, high-risk (such as del[17p], TP53-mutated, and IGHV-unmutated) patients with CLL.

In summary, treatment of the young, fit patient with CLL has evolved to include two primary options: fixed-duration CIT with FCR, or continuous BTK inhibitor monotherapy. Treatment choice is individualized based on cytogenetic and molecular risk profiling as well as on age, fitness, and, importantly, patient preferences.

5. The Canadian Landscape Today

There are many factors to consider when treating a young, fit patient with CLL. Molecular status, CIT eligibility, patient preferences, quality of life, duration of treatment, sequencing, short-term and long-term safety implications, insurance availability, and transplant eligibility are all important considerations. In addition, the young, fit population tends to be highly engaged in the treatment decision process and requires conversations with their oncologists to make decisions based on their individual situations and within provincial regulations.

In current Canadian practice, FCR is being chosen less often than previously, even in patients with low-risk features, due to toxicity issues and the long-term risk of secondary malignancies [35]. While the risk of lifetime acute myeloid leukemia and myelodysplastic syndromes was once believed to be about 1% after FCR, retrospective studies have found that lifetime risk actually ranges between 4% and 10% [36]. Other long-term issues with FCR include the potential for severe marrow toxicity and the need for immunoglobulin support after therapy [11].

BTK inhibitors demonstrate a different toxicity profile compared to CIT and choosing the right treatment for each individual to maximize efficacy and minimize toxicity is a key goal. Care must be taken in deciding to use BTK inhibitors in patients with moderate to severe bleeding disorders; concomitant use of anticoagulant/antiplatelet agents; prior Grade 3 or 4 atrial fibrillation; unstable cardiovascular disease such as hypertension or new ischemic heart disease; chronic skin conditions; and compliance with oral therapy. Other considerations of continuous therapy with an oral BTK inhibitor include the risk of skin cancer; the need for patients to see their oncologists or family physician at least every three months for vital sign measurements; the importance of interrupting BTK inhibitor therapy when surgery is planned; and the necessity of education for both patients and other health care professionals.
However, the availability of continuous oral therapies, such as ibrutinib, is an advantage when one considers patient values and nation-wide accessibility. Firstly, oral therapies provide convenience of at-home treatment to the patient with CLL and/or their caregiver [37,38]. In addition, these therapies preclude the need to travel for treatment appointments, which is a particular benefit to patients in large catchment areas that have challenges in travelling distances, and relieve the stress of frequent travel [37,39,40]. Finally, these options allow patients with CLL to continue working and not have to take time off work. This reduces disruptions to a routine schedule and helps maintain a sense of normalcy, providing a psychological benefit to many patients with CLL [37–40].

Shared decision-making is vital for any patient but may provide relatively higher value to the young, fit CLL population. While fixed-duration chemotherapy-based therapy has the potential for long-term disease control in some low-risk patients, long-term toxicity may arise. On the other hand, continuous oral targeted therapy has the potential for long-term disease control, and this needs to be balanced with toxicities that may arise in continuous therapies [11,35,36,41,42]. Each has benefits and concerns, and each patient is different. A risk-based algorithm is provided in Figure 6, with further practical considerations outlined in the associated table.

![Figure 6. Frontline treatment algorithm for young/fit patients with CLL. iwCLL = International Workshop on Chronic Lymphocytic Leukemia.](image)

### 6. Conclusions and Future Directions

Two decades ago, fludarabine monotherapy was associated with a 31% PFS at three years in young, fit patients with CLL [26]. Today, ibrutinib has been shown to result in an 89% PFS at three years in the same population [7]. Treatment of patients with CLL has come a long way and medicine never stops advancing. There are emerging therapies and novel combinations on the horizon, including second-generation and noncovalent BTK inhibitors permitting optimization of this important drug class [43–46].

As a clinician considers the appropriate therapy for their young, fit patient, risks and benefits need to be effectively communicated. For example, a 6-month course of FCR, while challenging to tolerate, may have the ability to achieve long-lasting remissions in certain low-risk populations without the need for retreatment [30]. Continuous oral BTKi
therapy, on the other hand, may result in long term disease remission in certain patients with high-risk features \cite{7,31,33}, but, by its very nature, presents a low but real risk of mutations in the binding site which may give rise to a higher risk of treatment-resistant disease \cite{9,22}. This risk may be less concerning in the future with the development of novel BTK inhibitors which bypass these resistant mechanisms \cite{46}. Finally, novel combinations, such as those that include BCL-2 inhibitors, present the possibility of durable response, in some patients, with time-limited therapy \cite{47–49}.

As new agents and combinations become available, the physician and patient will both benefit through the ability to further individualize treatment. Age, fitness, comorbidities, and molecular status characterize patients with varying likelihoods of therapeutic success, and growing numbers of options increase the likelihood the most appropriate treatment for every CLL patient has been chosen based on disease characteristics, provincial jurisdiction, and, most importantly, patient-related factors and benefits.

**Author Contributions:** All authors contributed to manuscript conceptualization, writing—original draft preparation, and writing—review and editing. All authors have read and agreed to the published version of the manuscript.

**Funding:** Funding for medical writing and project management was provided by Janssen Canada Inc.

**Acknowledgments:** The authors would like to acknowledge the assistance of CTC Communications, Carol Thomas of Deca Medical Writing, Carlie Russell, and Designs that Cell in developing the manuscript and figures.

**Conflicts of Interest:** M.K. serves on the advisory boards of Amgen, Janssen, Novartis, and Gilead. V.B. serves on the advisory boards of Janssen, Astra Zeneca and Abbvie. V.B. has research funding from LLSC, CIHR, CCMF, HCLF, Roche, Janssen, and Abbvie. J.C. serves on the advisory boards of Janssen, Gilead, Roche, Abbvie, Astra Zeneca. J.C. has research funding from CIHR. Funding for medical writing and project management was provided by Janssen Canada Inc. The funders were provided the opportunity to read the manuscript for scientific accuracy. The funders had no role in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Rozman, C.; Montserrat, E. Chronic lymphocytic leukemia. *N. Engl. J. Med.* 1995, 333, 1052–1057. [CrossRef] [PubMed]
2. Statistics Canada. Table 13-10-0111-01. Number and Rates of New Cases of Primary Cancer, by Cancer Type, Age Group and Sex. Available online: https://doi.org/10.25318/1310011101-eng (accessed on 25 May 2021).
3. Canadian Cancer Society. Chronic Lymphocytic Leukemia Statistics. Available online: https://www.cancer.ca/en/cancer-information/cancer-type/leukemia-chronic-lymphocytic-clf/statistics/?region=on (accessed on 25 May 2021).
4. Owen, C.; Gerrie, A.S.; Banerji, V.; Assouline, S.; Chen, C.; Robinson, K.S.; Lye, E.; Fraser, G. Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia. *Curr. Oncol.* 2018, 25, e461–e474. [CrossRef] [PubMed]
5. Shustik, C.; Bence-Bruckler, I.; Delage, R.; Owen, C.J.; Toze, C.L.; Coutre, S. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. *Ann. Hematol.* 2017, 96, 1185–1196. [CrossRef] [PubMed]
6. Jones, J.A.; Byrd, J.C. How will B-cell-receptor-targeted therapies change future CLL therapy? *Blood* 2014, 123, 1455–1460. [CrossRef] [PubMed]
7. Shanafelt, T.D.; Wang, X.V.; Kay, N.E.; Hanson, C.A.; O’Brien, S.; Barrientos, J.; Jelinek, D.F.; Braggio, E.; Leis, J.F.; Zhang, C.C.; et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. *N. Engl. J. Med.* 2019, 381, 432–443. [CrossRef]
8. Eichhorst, B.; Fink, A.M.; Bahlo, J.; Busch, R.; Kovacs, G.; Maurer, C.; Lange, E.; Köppler, H.; Kiehl, M.; Söker, M.; et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial. *Lancet Oncol.* 2016, 17, 928–942. [CrossRef]
9. Fischer, K.; Bahlo, J.; Fink, A.M.; Goede, V.; Herling, C.D.; Cramer, P.; Langerbeins, P.; von Tresckow, J.; Engelke, A.; Maurer, C.; et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. *Blood* 2016, 127, 208–215. [CrossRef]
10. Leukemia & Lymphoma Society of Canada. CLL Staging. Available online: https://www.llscanada.org/leukemia/chronic-lymphocytic-leukemia/diagnosis/cll-staging (accessed on 25 May 2021).
11. Hallek, M.; Cheson, B.D.; Catovsky, D.; Caligaris-Cappio, F.; Dighiero, G.; Döhner, H.; Hillmen, P.; Keating, M.; Montserrat, E.; Chiorazzi, N.; et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. *Blood* 2018, 131, 2745–2760. [CrossRef]
12. International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. *Lancet Oncol.* 2016, 17, 779–790. [CrossRef]  
13. Seftel, M.D.; Demers, A.A.; Banerji, V.; Gibson, S.B.; Morales, C.; Musto, G.; Pitz, M.W.; Johnston, J.B. High incidence of chronic lymphocytic leukaemia (CLL) diagnosed by immunophenotyping: A population-based Canadian cohort. *Leuk. Res.* 2009, 33, 1463–1468. [CrossRef]  
14. Yosifov, D.Y.; Wolf, C.; Stilgenbauer, S.; Mertens, D. From biology to therapy: The CLL success story. *Hempheres* 2019, 3, e175. [CrossRef] [PubMed]  
15. Andreani, G.; Carrà, G.; Lingua, M.F.; Maffeo, B.; Brancaccio, M.; Taulli, R.; Morotti, A. Tumor Suppressors in Chronic Lymphocytic Leukaemia: From Lost Partners to Active Targets. *Cancers* 2020, 12, 629. [CrossRef] [PubMed]  
16. Delgado, J.; Nadeu, F.; Colomer, D. Chronic lymphocytic leukaemia: From molecular pathogenesis to novel therapeutic strategies. *Haematologica* 2020, 105, 2205–2217. [CrossRef] [PubMed]  
17. Burger, J.A.; Tedeschi, A.; Barr, P.M.; Robak, T.; Owen, C.; Ghia, P.; Bairey, O.; Hillmen, P.; Bartlett, N.L.; Li, J.; et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukaemia. *N. Engl. J. Med.* 2015, 373, 2425–2437. [CrossRef] [PubMed]  
18. Fischer, K.; Al-Sawaf, O.; Bahlo, J.; Fink, A.M.; Tandon, M.; Dixon, M.; Robrecht, S.; Warburton, S.; Humphrey, K.; Samoylova, O.; et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. *N. Engl. J. Med.* 2019, 380, 2225–2236. [CrossRef] [PubMed]  
19. Furman, R.R.; Sharman, J.P.; Coutre, S.E.; Cheson, B.D.; Pagel, J.M.; Hillmen, P.; Barrientos, J.C.; Zelenetz, A.D.; Kipp, T.J.; Flinn, I.; et al. Idealisib and rituximab in relapsed chronic lymphocytic leukaemia. *N. Engl. J. Med.* 2014, 370, 997–1007. [CrossRef] [PubMed]  
20. Moreno, C.; Greil, R.; Demirkan, R.; Tedeschi, A.; Anz, B.; Larratt, L.; Simkovic, M.; Samaolova, O.; Novak, J.; Ben-Yehuda, D.; et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol.* 2019, 20, 43–56. [CrossRef]  
21. Shamar, J.P.; Egyed, M.; Jurczak, W.; Skarbink, A.; Pagel, J.M.; Flinn, I.W.; Kamdar, M.; Munir, T.; Walewska, R.; Corbett, G.; et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. *Lancet* 2020, 395, 1278–1291. [CrossRef]  
22. Woyach, J.A.; Ruppert, A.S.; Heerema, N.A.; Zhao, W.; Booth, A.M.; Ding, W.; Bartlett, N.L.; Brander, D.M.; Barr, P.M.; Rogers, K.A.; et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. *N. Engl. J. Med.* 2018, 379, 2517–2528. [CrossRef] [PubMed]  
23. Catoovsky, D.; Richards, S.; Matutes, E.; Oscier, D.; Dyer, M.; Bezares, R.; Pettitt, A.R.; Hamblin, T.; Milligan, D.W.; Child, J.A.; et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. *Lancet* 2007, 370, 230–239. [CrossRef]  
24. Eichhorst, B.F.; Busch, R.; Hopfinger, G.; Pasold, R.; Hensel, M.; Steinbrecher, C.; Siehl, S.; Jäger, U.; Bergmann, M.; Stilgenbauer, S.; et al. Fludarabine plus cyclophosphamide alone in first-line therapy of younger patients with chronic lymphocytic leukaemia. *Blood* 2006, 107, 885–891. [CrossRef]  
25. Flinn, I.W.; Neuberg, D.S.; Grever, M.R.; Dewald, G.W.; Bennett, J.M.; Paietta, E.M.; Hussein, M.A.; Appelbaum, F.R.; Larson, R.A.; Moore, D.F., Jr.; et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997. *J. Clin. Oncol.* 2007, 25, 793–798. [CrossRef]  
26. Rai, K.R.; Peterson, B.L.; Appelbaum, F.R.; Tallman, M.S.; Belch, A.; Morrison, V.A.; Larson, R.A. Long-term survival analysis of the North American intergroup study C9011 comparing fludarabine (F) and chlorambucil (C) in previously untreated patients with chronic lymphocytic leukaemia (CLL). *Blood* 2009, 114, 536. [CrossRef]  
27. Knauf, W.U.; Lissitchkov, T.; Aldaoud, A.; Liberati, A.M.; Loscertales, J.; Herbrecht, R.; Juliusson, G.; Postner, G.; Gercheva, L.; Goranov, S.; et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: Updated results of a randomized phase III trial. *Br. J. Haematol.* 2012, 159, 67–77. [CrossRef] [PubMed]  
28. Rai, K.R.; Peterson, B.L.; Appelbaum, F.R.; Kolitz, J.; Elias, L.; Shepherd, L.; Hines, J.; Threlatte, G.A.; Larson, R.A.; Cheson, B.D.; et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. *N. Engl. J. Med.* 2000, 343, 1750–1757. [CrossRef] [PubMed]  
29. Robak, T.; Dmoszynska, A.; Solal-Céligny, P.; Warzocha, K.; Loscertales, J.; Catalano, J.; Afanasiiev, B.V.; Larratt, L.; Geisler, C.H.; Montillo, M.; et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukaemia. *J. Clin. Oncol.* 2010, 28, 1756–1765. [CrossRef] [PubMed]  
30. Thompson, P.A.; Tam, C.S.; O’Brien, S.M.; Wierda, W.G.; Stingo, F.; Plunkett, W.; Smith, S.C.; Kantarjian, H.M.; Freireich, E.J.; Keating, M.J. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukaemia. *Blood* 2016, 127, 303–309. [CrossRef]  
31. Shanafelt, T.D.; Wang, V.; Kay, N.E.; Hanson, C.A.; O’Brien, S.M.; Barrientos, J.C.; Jelinek, D.F.; Braggio, E.; Leis, J.F.; Zhang, C.C.; et al. Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukaemia (CLL): Extended follow-up from the E1912 trial. *Blood* 2019, 134, 33. [CrossRef]  
32. Barr, P.M.; Owen, C.; Robak, T.; Tedeschi, A.; Bairey, O.; Burger, J.A.; Hillmen, P.; Coutre, S.E.; Devereux, S.; Grosicki, S.; et al. Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukaemia.
leukemia. In Proceedings of the 2021 American Society of Clinical Oncology Annual Meeting, Virtual/Online, 4–8 June 2021; Poster 7523.

33. Byrd, J.C.; Furman, R.R.; Coutre, S.E.; Flinn, I.W.; Burger, J.A.; Blum, K.; Sharman, J.P.; Wierda, W.; Zhao, W.; Heerema, N.A.; et al. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. *Clin. Cancer Res.* 2020, 26, 3918–3927. [CrossRef]

34. Canadian Agency for Drugs and Technologies in Health. Pan-Canadian Oncology Drug Review. Provincial Funding Summary: Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (Previously Untreated) (pCODR 10085). 2020, pp. 1–2. Available online: https://www.cadth.ca/sites/default/files/pcodr/pcodr-provfund_ibrutinib_imbruvica-clf-sll-preun.pdf (accessed on 12 May 2021).

35. Lukenbill, J.; Kalaycio, M. Fludarabine: A review of the clear benefits and potential harms. *Leuk. Res.* 2013, 37, 986–994. [CrossRef] [PubMed]

36. Tam, C.S.; O’Brien, S.; Wierda, W.; Kantarjian, H.; Wen, S.; Do, K.A.; Thomas, D.A.; Cortes, J.; Lerner, S.; Keating, M.J. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. *Blood* 2008, 112, 975–980. [CrossRef]

37. Borner, M.; Scheithauer, W.; Twelves, C.; Maroun, J.; Wilke, H. Answering patients’ needs: Oral alternatives to intravenous therapy. *Oncologist* 2001, 6, 12–16. [CrossRef]

38. Halfdanarson, T.R.; Jatoi, A. Oral cancer chemotherapy: The critical interplay between patient education and patient safety. *Curr. Oncol. Rep.* 2010, 12, 247–252. [CrossRef]

39. Tucker, S.J.; Pelusi, J. Capecitabine versus 5-FU in metastatic colorectal cancer: Considerations for treatment decision-making. *Community Oncol.* 2006, 3, 19–27. [CrossRef]

40. Wood, L. A review on adherence management in patients on oral cancer therapies. *Eur. J. Oncol. Nursing* 2012, 16, 432–438. [CrossRef] [PubMed]

41. Janssen Inc. *Imbruvica® (ibrutinib) Product Monograph*; Janssen Inc.: Beerse, Belgium, 28 May 2021.

42. Clinical Guidance on COVID-19 Vaccines for People with Solid Cancers. Available online: http://www.bccdc.ca/Health-Info-Site/Documents/COVID-19_vaccine/Solid_Cancer_Clinical_Guidance.pdf (accessed on 18 April 2021).

43. Byrd, J.C.; Hillmen, P.; Ghia, P.; Kater, A.P.; Chanan-Khan, A.; Furman, R.R.; O’Brien, S.M.; Yenerel, M.N.; Illes, A.; Kay, N.E.; et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. *J. Clin. Oncol.* 2021, 39, 7500. [CrossRef]

44. Gu, D.; Tang, H.; Wu, J.; Li, J.; Miao, Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. *J. Hematol. Oncol.* 2021, 14, 40. [CrossRef]

45. Hillmen, P.; Hillmen, B.; Brown, J.R.; Lamanna, N.; O’Brien, S.; Tam, C.S.; Qiu, L.; Kazmierczak, M.; Zhou, K.; Simkovic, M.; et al. First interim analysis of alpine study: Results of a phase 3 randomized study of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma. In Proceedings of the 2021 European Hematology Association Virtual Congress, 9–17 June 2021; Oral Abstract LB1900.

46. Mato, A.R.; Pagel, J.M.; Comombs, C.C.; Shah, N.N.; Lamanna, N.; Leck-Mararida, E.; Eyre, T.A.; Woyach, J.A.; Wierda, W.G.; Cheah, C.Y.; et al. LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated chronic lymphocytic leukemia. In Proceedings of the 2020 American Society of Hematology Annual Meeting & Exposition, Virtual/Online, 7 December 2020; Abstract 542.

47. Al-Sawaf, O.; Zhang, C.; Robrecht, S.; Tandon, M.; Panchal, A.; Fink, A.M.; Tausch, E.; Ritgen, M.; Kreuzer, K.A.; Kim, S.Y.; et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 4-year follow-up analysis of the randomized CLL14 study. In Proceedings of the 2021 European Hematology Association Virtual Congress, 9–17 June 2021; Abstract S146.

48. Kater, A.; Owen, C.; Moreno, C.; Follows, G.; Munir, T.; Levin, M.D.; Benjamini, O.; Janssens, A.; Osterborg, A.; Robak, T.; et al. Fixed-duration ibrutinib and venetoclax (I+V) versus chlorambucil plus obinutuzumab (Clb+O) for first-line (1L) chronic lymphocytic leukemia (CLL): Primary analysis of the phase 3 glow study. In Proceedings of the 2021 European Hematology Association Virtual Congress, 9–17 June 2021; Abstract LB1902.

49. Ghia, P.; Allan, J.N.; Siddiqui, T.; Kipps, T.J.; Jacobs, R.; Opat, S.; Barr, P.M.; Tedeschi, A.; Trentin, L.; Bannerji, R.; et al. Fixed-duration (FD) first-line treatment (Tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study. In Proceedings of the 2021 American Society of Clinical Oncology Annual Meeting, Virtual, 4–8 June 2021; Oral Abstract 7501.